Gearing AI to Fight Pandemics: a Novel COVID-19 Drug Candidate Announced

by Andrii Buvailo, PhD          News

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

  
Topics: AI & Digital   
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Hong Kong-based clinical stage drug discovery company Insilico Medicine just announced the nomination of a novel preclinical drug candidate for treating COVID-19, de novo designed using the company’s artificial intelligence platform Chemistry42. The new drug candidate is a 3CL protease inhibitor which is unique from existing drugs in its class because it can be rapidly produced.

Image credit CROCOTHERY, iStock

 

The COVID-19 pandemic

According to a by Innophore, the Coronavirus (WHO 2019nCoV) that caused the historical global COVID-19 pandemics is a positive sense, single stranded RNA beta coronavirus, a member of Beta-CoV lineage B (subgenus Sarbecovirus), possessing paramount ability for human-to-human transmission. The RNA sequence is around 30 kb in length. 

Continue reading

This content available exclusively for BPT Mebmers

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email